Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys.

Sharif NA, Katoli P, Scott D, Li L, Kelly C, Xu S, Husain S, Toris C, Crosson C.

Drug Dev Res. 2014 Jun;75(4):211-23. doi: 10.1002/ddr.21174. Epub 2014 May 2.

PMID:
24796320
2.

Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule.

Sharif NA, Li L, Katoli P, Xu S, Veltman J, Li B, Scott D, Wax M, Gallar J, Acosta C, Belmonte C.

Exp Eye Res. 2014 Nov;128:170-80. doi: 10.1016/j.exer.2014.10.008. Epub 2014 Oct 11.

PMID:
25307520
3.

Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.

Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C.

Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1.

PMID:
18992242
4.

Human non-pigmented ciliary epithelium bradykinin B2-receptors: receptor localization, pharmacological characterization of intracellular Ca(2+) mobilization, and prostaglandin secretion.

Sharif NA, Wang Y, Katoli P, Xu S, Kelly CR, Li L.

Curr Eye Res. 2014 Apr;39(4):378-89. doi: 10.3109/02713683.2013.816324. Epub 2013 Jul 25.

PMID:
24624903
5.

Trabecular meshwork bradykinin receptors: mRNA levels, immunohistochemical visualization, signaling processes pharmacology, and linkage to IOP reduction.

Sharif NA, Katoli P, Kelly CR, Li L, Xu S, Wang Y, Klekar L, Earnest D, Yacoub S, Hamilton G, Jacobson N, Shepard AR, Ellis D.

J Ocul Pharmacol Ther. 2014 Feb;30(1):21-34. doi: 10.1089/jop.2013.0105. Epub 2013 Nov 16.

PMID:
24236827
6.

Protein expression, biochemical pharmacology of signal transduction, and relation to intraocular pressure modulation by bradykinin B₂ receptors in ciliary muscle.

Sharif NA, Xu S, Li L, Katoli P, Kelly CR, Wang Y, Cao S, Patil R, Husain S, Klekar L, Scott D.

Mol Vis. 2013 Jun 15;19:1356-70. Print 2013.

7.
8.

AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist.

Sharif NA, McLaughlin MA, Kelly CR.

J Ocul Pharmacol Ther. 2007 Feb;23(1):1-13.

PMID:
17341144
9.

Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.

Sharif NA, McLaughlin MA, Kelly CR, Xu S, Crider JY, Williams GW, Parker JL.

J Ocul Pharmacol Ther. 2006 Oct;22(5):291-309.

PMID:
17076623
10.

The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor.

Bellucci F, Meini S, Cucchi P, Catalani C, Giuliani S, Zappitelli S, Rotondaro L, Quartara L, Giolitti A, Maggi CA.

Eur J Pharmacol. 2004 May 3;491(2-3):121-5.

PMID:
15140628
11.

Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction.

Sharif NA, Kelly CR, McLaughlin M.

Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4001-10.

PMID:
16936116
13.

Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657).

Gobeil F Jr, Montagne M, Inamura N, Regoli D.

Immunopharmacology. 1999 Sep;43(2-3):179-85.

PMID:
10596851
14.

Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997.

Asano M, Hatori C, Sawai H, Johki S, Inamura N, Kayakiri H, Satoh S, Abe Y, Inoue T, Sawada Y, Mizutani T, Oku T, Nakahara K.

Br J Pharmacol. 1998 Jun;124(3):441-6.

15.

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H.

Exp Eye Res. 2004 Apr;78(4):767-76.

PMID:
15037111
16.
17.

Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses.

Paquet JL, Luccarini JM, Fouchet C, Defrêne E, Loillier B, Robert C, Bélichard P, Cremers B, Pruneau D.

Br J Pharmacol. 1999 Mar;126(5):1083-90.

18.

Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Nakahara K, Kojo H, Oku T, Notsu Y.

Mol Pharmacol. 1997 Jul;52(1):16-20.

19.

Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.

Prasanna G, Carreiro S, Anderson S, Gukasyan H, Sartnurak S, Younis H, Gale D, Xiang C, Wells P, Dinh D, Almaden C, Fortner J, Toris C, Niesman M, Lafontaine J, Krauss A.

Exp Eye Res. 2011 Sep;93(3):256-64. doi: 10.1016/j.exer.2011.02.015. Epub 2011 Mar 3.

PMID:
21376717
20.

Supplemental Content

Support Center